title: The effect of repeated administrations of granulocyte colony stimulating factor for blood stem cells mobilization in patients with progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy.
abstract: Granulocyte colony stimulating factor (GCSF) may boost physiological stem cell repair system in patients with cerebral lesions. Atypical parkinsonisms (PSP, CBD, MSA) are characterized by rapidly progressive course without significant benefit from current therapies. We treated 11 patients with atypical parkinsonism (MSA n=4, PSP n=5, CBD n=2) with GCSF (5mcg/kg s.c. daily for 6 days/month) for 3 months. We assessed CBC, CD34+ cells, routine biochemical and coagulation tests, UPDRS motor scores and safety. We did not observe significant adverse events during and following GCSF treatment. One patient withdrew informed consent. Three patients complained about bone pain that improved following steroid treatment. Four patients perceived a subjective benefit after treatment was completed. UPDRS motor score improved in three patients, remained stable in two and worsened in five. GCSF can be safely administered to patients with atypical parkinsonism and potentially meaningful clinical changes may be observed in some patients. These results are encouraging and warrant further studies.
authors.affiliation: Parkinson Institute, Istituti Clinici di Perfezionamento, Via Bignami 1, 20126 Milan, Italy.
authors.forename: Gianni
authors.initials: G
authors.lastname: Pezzoli
authors.forename: Silvana
authors.initials: S
authors.lastname: Tesei
authors.forename: Margherita
authors.initials: M
authors.lastname: Canesi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Sacilotto
authors.forename: Montefusco
authors.initials: M
authors.lastname: Vittorio
authors.forename: Yoshi
authors.initials: Y
authors.lastname: Mizuno
authors.forename: Hideki
authors.initials: H
authors.lastname: Mochizuki
authors.forename: Angelo
authors.initials: A
authors.lastname: Antonini
mesh_terms: D000368:Aged; D018952:Antigens, CD34 / Q000097:blood; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000628:therapy*; D009410:Nerve Degeneration / Q000628:therapy*; D009460:Neurologic Examination; D010300:Parkinson Disease / Q000628:therapy; D013494:Supranuclear Palsy, Progressive / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor